Reviewing Key Points from the Phase III MURANO Trial in CLL
William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.
William G. Wierda, MD, PhD, professor in the department of leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the take home message from the phase III MURANO trial that identified venetoclax (Venclexta) plus rituximab (Rituxan) as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
There are patients with CLL that achieve a deep remission by the end of 2-year treatment. Wierda says this remission and progression-free survival can be maintained after patients come off treatment.
